Open AccessPharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system
Author(s) -
A.Yu. Kulikov,
V.G. Serpik,
А. М. Лила
Publication year - 2022
Publication title -
sovremennaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 2310-158X
pISSN - 1996-7012
DOI - 10.14412/1996-7012-2022-2s-1-17
Subject(s) - biosimilar , medicine , context (archaeology) , rheumatoid arthritis , psoriatic arthritis , antirheumatic drugs , etanercept , infliximab , health care , pharmacoeconomics , antirheumatic agents , intensive care medicine , disease , economic growth , economics , paleontology , biology